重组人抗HBsAg-Fab阻断肝移植后HBV再感染的体外研究  

The recombinant antibody HBsAg-Fab of hepatitis B virus to block hepatitis B reinfection after liver transplantation: a research in vitro

作　　者：潘桃[1] 唐莉[1] 陈知水[1] 王大为[1] 程敦秀[1] 郭晖[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院器官移植研究所教育部卫生部重点实验室,湖北武汉430030

出　　处：《中国普通外科杂志》2007年第8期758-762,共5页China Journal of General Surgery

基　　金：国家自然科学基金资助项目(30471695)

摘　　要：目的研究重组合成抗乙型肝炎病毒(HBV)表面抗原(HBsAg)的小分子抗体Fab阻断肝移植后乙肝病毒再感染的作用效应。方法通过体外抗原黏附实验,补体毒实验和病毒感染实验,计算抗原黏附率、细胞死亡率和细胞感染率,进行统计分析,研究抗体Fab的功能效应。结果在有、无重组抗体存在时,组间的抗原黏附率、细胞死亡率及细胞感染率对比,差异均有显著性(均为P<0.05),实验数据在统计学上有显著差异。结论重组合成抗体Fab能阻断抗原对靶细胞的黏附,能介导补体毒杀伤靶细胞,降低HBV对人原代肝细胞的感染率。基因重组的小分子抗体Fab的体外效应实验为其在体内临床应用打下基础。Objective To study the effect of recombinant antibody HBsAg - Fab of hepatitis B virus （ HBV ） to block hepatitis B reinfection after liver transplantation. Methods The functional efficiency of antibody Fab in blocking hepatitis B reinfection after LT was analysis and studied by vitro infection test, complement toxicity assay and virus infection test, calculated the antibody absorption rate and cell death rate and cell infection rate, Results When the group with and the group without recombinant antibody Fab were compared, the antibody absorption rate, cell death rate and cell infection rate between the 2 groups showed sigificant defference （ P 〈 0. 05 ）. The tese data .,had significant statistical defference. Conclusions Recombinant antibody Fab can block antibody absorption by the target cell, can induce complement-dependent toxic death and damage of target cells, and decrease the HBV infection rate of primary human hepatocytes. The in vitro efficacy test of recombinant gene antibody Fab can be a basis for its use clinically in vivo.

关 键 词：:肝移植 肝炎病毒 乙型/免疫学 重组人抗HbsAG-Fab 手术后并发症/预防与控制 

分 类 号：R617[医药卫生—外科学] R341.1[医药卫生—临床医学]